Skip to content

In the BioHarmony Drug Report Database

Dabigatran etexilate

Pradaxa (dabigatran etexilate) is a small molecule pharmaceutical. Dabigatran etexilate was first approved as Pradaxa on 2008-03-17. It is used to treat pulmonary embolism in the USA. It has been approved in Europe to treat replacement arthroplasty and venous thromboembolism. It is known to target prothrombin. Pradaxa's patents are valid until 2031-01-20 (FDA).
Trade Name Pradaxa
Common Name Dabigatran etexilate
Indication pulmonary embolism, replacement arthroplasty, venous thromboembolism
Drug Class Thrombin inhibitors (argatroban type)
Dabigatran etexilate
Get full access now